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Abstract
Background: Bacterial translocation plays important role in the complications of liver cirrhosis. Antibody formation against
various microbial antigens is common in Crohn’s disease and considered to be caused by sustained exposure to gut
microflora constituents. We hypothesized that anti-microbial antibodies are present in patients with liver cirrhosis and may
be associated with the development of bacterial infections.
Methodology/Principal Findings: Sera of 676 patients with various chronic liver diseases (autoimmune diseases:266, viral
hepatitis C:124, and liver cirrhosis of different etiology:286) and 100 controls were assayed for antibodies to Saccharomyces
cerevisiae(ASCA) and to antigens derived from two intestinal bacterial isolates (one gram positive, one gram negative,
neither is Escherichia coli). In patients with liver cirrhosis, we also prospectively recorded the development of severe
episodes of bacterial infection. ASCA and anti-OMP PlusTM antibodies were present in 38.5% and 62.6% of patients with
cirrhosis and in 16% and 20% of controls, respectively (p,0.001). Occurrence of these antibodies was more frequent in cases
of advanced cirrhosis (according to Child-Pugh and MELD score; p,0.001) or in the presence of ascites (p,0.001). During
the median follow-up of 425 days, 81 patients (28.3%) presented with severe bacterial infections. Anti-microbial antibody
titers (p= 0.003), as well as multiple seroreactivity (p= 0.036), was associated with infectious events. In logistic regression
analysis, the presence of ascites (OR:1.62, 95%CI:1.16–2.25), co-morbidities (OR:2.22, 95%CI:1.27–3.86), and ASCA positivity
(OR:1.59, 95%CI:1.07–2.36) were independent risk factors for severe infections. A shorter time period until the first infection
was associated with the presence of ASCA (p= 0.03) and multiple seropositivity (p= 0.037) by Kaplan-Meier analysis, and
with Child-Pugh stage (p= 0.018, OR:1.85) and co-morbidities (p,0.001, OR:2.02) by Cox-regression analysis.
Conclusions/Significance: The present study suggests that systemic reactivity to microbial components reflects
compromised mucosal immunity in patients with liver cirrhosis, further supporting the possible role of bacterial
translocation in the formation of anti-microbial antibodies.
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Introduction
Bacterial infections are associated with increased morbidity and
mortality in patients with liver cirrhosis. A wide range of bacterial
infections can decompensate liver function and lead to deteriora-
tion or death in patients with cirrhosis [1,2]. Bacterial infection
itself, as well as inflammatory mediators, have been confirmed as
potential trigger factors in many complications of liver cirrhosis,
including variceal bleeding, hepatic encephalopathy, renal failure
or impairment in clotting factors [3,4]. Confirmed risk factors for
bacterial infections are advanced disease classified by Child-Pugh
stage [5,6] and the presence of gastrointestinal hemorrhage [7,8].
Regardless of the severity of the hepatic insufficiency, the
development of infection significantly increases the mortality rate.
The in-hospital mortality of cirrhotic patients with infection is
more than twice that of patients without infection. Various
infections are directly responsible for up to 50% of the deaths
among patients with liver cirrhosis [1,6].
An important characteristic of infections in liver cirrhosis is the
high incidence of episodes caused by enteric organisms [1,2].
Bacterial translocation, the passage of bacteria or their products
from the gut into the circulation, is a major mechanism in the
development of these infections [9]. The remarkable impact of
bacterial translocation on the pathogenesis of the disease is
highlighted by evidence that selective intestinal decontamination
with oral antibiotics reduces the overall risk of infections, and
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improves short-term survival in high-risk patients [10]. In the
absence of overt infections, norfloxacin also normalizes elevated
proinflammatory cytokine levels and increases vascular resistance
in patients with ascites who present with a high lipopolysaccha-
ride-binding protein (LBP) level [11,12]. The development of
bacterial resistance as a harmful complication of the antibiotic
prophylaxis however, is an emerging problem [13,14]. Detection
of bacterial deoxyribonucleic acid (DNA) in blood using the
polymerase chain reaction is regarded as a sensitive marker for
assessing bacterial translocation [15]. Unfortunately, clinical
practice is still lacking reliable and specific serological methods
for detecting the presence and extent of bacterial translocation.
Our group has recently hypothesized that the presence of
serological responses to various microbial antigens (e.g. phospho-
peptidomannan cell-wall component of Saccharomyces cerevisiae
[ASCA], glycans or complex gut bacterial protein lysates [OMP
PlusTM]) might be reflections of the sustained systemic exposure to
the constituents of the gut microflora due to enhanced bacterial
translocation [16]. These anti-microbial antibodies are regarded as
characteristic markers for complicated, small-bowel Crohn’s
disease [17,18]. Patients with untreated celiac disease however,
may also display a similar qualitative and quantitative serological
response [16,19,20]. Similar to Crohn’s disease, the highest
antibody prevalence and titers in celiac patients are associated
with the most severe form of the clinical presentation: malabsorp-
tion. This finding is in line with the hypothesis that among celiac
patients, malabsorption is the most pronounced clinical conse-
quence of the intestinal damage [21]. Similarly, in liver cirrhosis
inflammation of the small bowel is notable [22] and becomes more
pronounced with disease progression. Two thirds of patients with
cirrhosis who underwent capsule endoscopy showed mucosal
inflammatory-like abnormalities [23]. Alterations of small bowel
morphology, like partial villous atrophy and mild-to-moderate
increase in lamina propria infiltrate, as well as an increase in
intraepithelial lymphocytes were also demonstrated in patients
with cirrhosis [24]. Fecal calprotectin levels, which indicate
intestinal inflammation, and are widely used to evaluate intestinal
inflammation in patients with inflammatory bowel disease were
found increased in liver cirrhosis and concentrations were
significantly associated with the severity of inflammation [25]. It
is thus reasonable to hypothesize that the anti-microbial antibodies
may also present in patients with cirrhosis and may be associated
with the clinical course of the disease. At present however, there
are no data concerning anti-microbial antibodies in liver cirrhosis
and its complications.
The aim of our study was to investigate the prevalence of ASCA
and anti-OMP PlusTM antibodies in a large Hungarian cohort of
patients with chronic liver disease of different etiologies with or
without cirrhosis. We also aimed to evaluate the possible
interaction between the anti-microbial serologic responses and
the disease severity in patients with cirrhosis. Finally, we
conducted a follow-up observational study to investigate the
presence of these anti-microbial antibodies as markers of bacterial
translocation and potential risk factors for the development of
severe bacterial infection in liver cirrhosis.
Methods
1. Patient cohort
Six-hundred-seventy-six patients with various chronic liver
diseases were investigated. Sera of patients with autoimmune liver
diseases (ALD) (n = 266, male/female ratio [m/f]: 102/164, age:
51.1616.1 years; including primary biliary cirrhosis [PBC,
n = 153], primary sclerosing cholangitis [PSC, n = 59], autoim-
mune hepatitis [AIH, n = 54]), and chronic hepatitis C (chronic
HCV, n = 124, m/f: 49/75, age: 53.6611.7 years) were collected
from five Hungarian Hepatology Centers (Debrecen University,
Budapest Semmelweis University, Pecs University, Miskolc
Borsod-Abauj Zemplen County Hospital, and Miskolc Szent
Ferenc Hospital). The diagnosis of primary biliary cirrhosis was
based on biochemical evidence of cholestasis, serum anti-
mitochondrial antibodies (AMA) and/or PBC-specific AMA-M2
positivity, compatible histology, and the exclusion of extrahepatic
homeostasis [26]. The diagnosis of PSC was based on biochemical
evidence of cholestasis and the characteristic cholangiographic
findings of bile duct stenoses and dilatations. In most cases, it was
confirmed by compatible histology findings [27]. The diagnosis of
AIH was based on exclusion of other major causes of liver damage,
including alcoholic, viral, drug- and toxin-induced, and hereditary
liver disease, and using the scoring system of the International AIH
Group [28]. The diagnosis of chronic HCV was based on positive
HCV ribonucleic acid, elevated liver function tests (.2xULN for
more then 6 months) and compatible liver biopsy, if available. The
central coordination of sample and database management was
done by the Gastroenterology Division of the 2nd Department of
Medicine, Debrecen University (M.P. and I.T.). The control group
consisted of 100 age- and gender-matched healthy individuals (m/
f: 47/53, age: 48.1615.5 yrs) selected from consecutive blood
donors in Debrecen and Budapest. The control subjects did not
have any known gastrointestinal or liver diseases.
Serum samples were also obtained from 286 consecutive
patients with cirrhosis of different etiologies (m/f: 161/125, age:
56.3610.7 years) at the Gastroenterology Division of the 2nd
Department of Medicine (Debrecen University) during the period
from May 2006 to April 2008. The median disease duration was 3
years [IQR, 1–6 years] among cirrhotic patients at the time of the
involvement. The clinical data of these patients are summarized in
Table 1. The etiology of cirrhosis was alcoholic in 180 (63.0%),
HCV-related in 87 (30.4%), and various other etiologies in 19
(6.6%). Exclusion criteria were evidence of gastrointestinal
bleeding or bacterial infection in the preceding 6 weeks, and
prophylactic treatment with non-absorbable antibiotics in the
preceding 6 months. The diagnosis of cirrhosis was based on
clinical, biochemical, ultrasonographic and, when available,
histological features. Clinical data, including age, age at onset,
etiology and severity of cirrhosis, presence and grade of ascites,
encephalopathy, esophageal varices, prior episode of variceal
bleeding, and co-morbidities were collected. Myocardial infarc-
tion, congestive heart failure, peripheral arterial disease, cerebro-
vascular disease, chronic pulmonary disease, chronic renal failure,
diabetes mellitus, cancer, including hepatocellular carcinoma,
were the co-morbidity diagnoses taken into account during data
collection. Severity of the cirrhosis was graded according to the
Child–Pugh classification [29] and the model for end-stage liver
disease (MELD) score [30] was also calculated. After the blood
sampling, cirrhotic patients were followed until April 1, 2009 or
death/lost of follow up (median follow-up: 425 days [interquartile
range, IQR: 107-732]), for the occurrence of severe bacterial
infections. Infectious episodes were identified through inpatient
medical records (n = 479), reviewing clinical symptoms, appear-
ance of fever, laboratory data (absolute or relative elevation of the
white blood cell count with a left-shift and elevated serum levels of
high-sensitivity C-reactive protein and/or procalcitonin), including
microbiological culture results, if available, findings of imaging
techniques, and the effect of antibiotic treatment by two
independent gastroenterologists (M. P. and Zs.V.). Autopsy
records (n = 88) were also assessed in cases of death. The following
bacterial infections were considered severe: pneumonia (upper
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respiratory tract infections were excluded), infections of biliary
tract (cholecystitis, cholangitis, liver abscess), urinary tract
infections (uncomplicated cystitis were excluded), endocarditis,
osteomyelitis, infections of skin and soft tissue if associated with
bacteraemia, spontaneous bacterial peritonitis and bacteriaemia.
The diagnosis of spontaneous bacterial peritonitis was made if the
ascitic fluid contained more than 250 polymorphonuclear cells per
mm3, with or without positive culture, and in the absence of an
intra-abdominal source of infection. Bacteriaemia was considered
when clinical symptoms and signs of infection were present and
confirmed by the microbiological demonstration of the causative
organism from the blood culture in the absence of site-specific
infection. Other infectious episodes were diagnosed on the basis of
conventional criteria.
2. Ethical considerations
The study protocol was approved by the Ethical and Science
Committee of the University of Debrecen. Each patient was
informed of the nature of the study and signed an informed
consent form.
3. Antibody assays
Collected sera were frozen at 280uC until testing. Commer-
cially available ELISA kits were used to test for the presence of
ASCA IgG, ASCA IgA, and anti-OMP PlusTM IgA (QUANTA
LiteTM, INOVA Diagnostics, San Diego, CA) antibodies in sera.
Examinations were performed in a blinded fashion, without
knowledge of patients’ diagnosis or other clinical information in
the Laboratory of INOVA Diagnostics, Inc., San Diego, CA by
Z.S.
ASCA ELISA assay. Both serum IgG and IgA levels of anti-
Saccharomyces cerevisiae antibodies (ASCA) were evaluated separately
according to the manufacturer’s protocol (ASCA IgG, ASCA IgA,
QUANTA LiteTM, INOVA Diagnostics). The results are
presented as arbitrary units with a cut-off value for positivity of
25 Units. Sera were documented both, in absolute values and in
frequency of positivity.
OMP PlusTM ELISA assay. IgA antibodies against multiple
bacterial proteins derived from two species of intestinal bacteria
(one gram positive and one gram negative) were detected
according to the manufacturer’s protocol (QUANTA Lite TM
OMP PLUSTM ELISA, INOVA Diagnostics). Neither bacteria
are from the phylum proteobacteria, of which Escherichia coli is a
member. The results are presented as arbitrary units with a cut-off
value for positivity of 25 Units. Sera were documented both, in
absolute values and in frequency of positivity. For every sample,
two analyses on the same plate were carried out.
In order to evaluate the variation in the anti-microbial antibody
level, duplicate serum samples were taken from a subgroup of
cirrhotic patients (n = 62) at different time points with a median
time interval of 204 days [IQR, 71–245 days].
4. Detection of lipopolysaccharide-binding protein
Collected sera were frozen at 280uC until testing. LBP was
determined in sera of patients with liver cirrhosis and healthy
controls by a solid-phase enzyme-linked immunosorbent assay
based on the sandwich principle (Hycult Biotechnology, Uden,
Netherlands). The lower assay sensitivity limit was 1 ng/mL. For
every sample, two analyses on the same plate were carried out and
the mean value was used. In a subgroup of cirrhotic patients
(n = 102), another serum samples were taken at the time of
bacterial infection in order to investigate the changes in serum
LBP during bacterial infections. The assays were performed at the
Department of Clinical Biochemistry and Molecular Pathology,
University of Debrecen.
5. Statistical methods
Variables were tested for normality with Shapiro Wilk’s W test.
T-test with separate variance estimates, x2-test, x2-test with Yates
correction, and ANOVA with post hoc Scheffe were used to
evaluate differences between cirrhosis and other liver disease
controls, as well as within subgroups of patients with cirrhosis, as
appropriate. Results are expressed as odds ratio (OR) with 95%
confidence intervals (95% CI). Kaplan-Meier survival curves were
plotted for analysis with LogRank and Breslow tests. Additionally,
logistic regression analysis and forward stepwise Cox-regression
analysis was used to assess the association between categorical
clinical variables and risk of and time to significant clinical
infection. A p value of ,0.05 was considered as significant. For
statistical analysis, SPSS15.0 (SPSS Inc, Chicago, IL) was used,
with the help of a statistician (Dr. Peter Vargha).
Results
1. Anti-microbial serological markers in patients with
chronic liver diseases
The prevalence rates of ASCA and anti-OMP PlusTM
antibodies in patients with various chronic liver diseases are
presented in Table 2. The rate of ASCA IgA and/or IgG and also
anti-OMP PlusTM IgA seropositivity was greatly elevated in
patients with liver cirrhosis compared to healthy controls
(ORASCAeither: 3.28, 95% CI: 1.83–5.89; ORanti-OMP Plus
TM:
Table 1. Clinical characteristics of patients with liver cirrhosis.
Liver cirrhosis (n =286)
Gender (male/female) 161/125
Age (mean ± SD, years) 56.3610.7
Median (IQR, years) 56 (50–64)
Child-Pugh stage, n
A 96
B 107
C 76
NA 7
Meld score (points) 14.666.5
Serum bilirubin (mmol/L) 65.8697.4
Serum albumin (g/L) 33.567.8
Platelet (G/L) 121.1669.2
Co-morbidities present, n (%) 123 (43.1%)
One 93
Two 24
Three or more 6
HCC, n (%) 33 (11.5%)
Mean follow-up ± SD (days) 4406347
Median follow-up, IQR (days) 425 (107–732)
Patients with severe bacterial infections, n(%) 81 (28.3%)
One 45
Two 22
Three 14
SD: standard deviation, IQR: inter-quartile range, HCC: hepatocellular carcinoma,
NA: not available.
doi:10.1371/journal.pone.0012957.t001
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6.69, 95% CI: 3.88–11.55) or chronic liver diseases without
cirrhosis (p,0.001 for both). Seropositivity rates were even lower
in patients with chronic HCV without cirrhosis as compared to the
controls, other liver diseases, or patients with cirrhosis (p,0.001
for all). The rates of ASCA and anti-OMP PlusTM positivity were
not overall different overall in patients with autoimmune liver
disease without cirrhosis as compared to the controls. A more
subtle analysis of this group revealed that the frequency of ASCA
positivity was also significantly higher in a small group of patients
with PSC (p= 0.04), but not in those with PBC or AIH. Regarding
anti-OMP PlusTM IgA, no similar tendency was observed. In
patients with cirrhosis, the serological profile was not different
based on disease etiology (data not shown). 10.4% of patients with
cirrhosis were triple-positive for ASCA IgA, ASCA IgG, and anti-
OMP PlusTM IgA antibodies, compared with only 1% of control
subjects (p,0.0001). Only one patient was triple-positive in the
ALD group and none in the chronic HCV group.
In patients with liver cirrhosis, seropositivity rates increased
gradually according to disease severity, as rated by the Child-Pugh
stage (see Table 3) or MELD score (data not shown), for both
ASCA IgA and anti-OMP PlusTM IgA. 18.4% of patients with
Child C cirrhosis were triple-positive for ASCA IgA, ASCA IgG,
and anti-OMP PlusTM IgA antibodies, compared with only 4.2%
in Child A and 10.3% in Child B groups (p,0.01 for both). The
same association was found if the triple seropositivity rate was
calculated for the MELD inter-quartile ranges (IQR) (1st quartile:
1.7% 2nd quartile: 6.6% 3rd quartile: 14.3% 4th quartile: 20.3%,
p,0.01). Similarly to the rates of seropositivity, the more severe
the disease, the higher were the titers of the ASCA IgA and anti-
OMP PlusTM IgA, but not the titer of ASCA IgG (see Figure 1).
The occurrence of either individual anti-microbial antibodies or
multiple seropositivity was associated with the presence of ascites
(ORASCA either: 1.93, 95% CI: 1.19–3.14; ORanti-OMP Plus
TM: 3.08,
95% CI: 1.86–5.11) (see Table 4) as well as the quantitative anti-
OMP PlusTM IgA serological response (median, no ascites vs.
ascites: 25.4 vs. 41.5 Units, p,0.001).
Median serum LBP levels were not statistically different
between patients with liver cirrhosis and healthy subjects (21,
860 vs. 19, 333 ng/ml, p = 0.08). No correlation was found
between LBP levels and the disease severity or the presence of
ascites. Furthermore, serum LBP levels were not different in
cirrhotic patients with and without ASCA IgG/IgA, and anti-
OMP IgA antibodies or if a combination of anti-microbial
antibodies was used (data not shown).
2. Clinical and laboratory predictors for the development
of severe infection
Bacterial infections: general characteristics and
microbiologic results. Among the 286 cirrhotic patients, a
total of 176 severe infectious episodes were identified during
hospitalizations. 28.3% of the patients presented with some type of
infection (Table 1). Of the patients with infection, 44.4% suffered
more than one episode. The distribution of different severe
infections was as follows: 28.2% spontaneous bacterial peritonitis,
21.5% pneumonia, 12.5% urinary tract infection, 8.7% skin and
soft tissue infections and 12.6% miscellaneous. The origin of the
infection could not be identified in 16.5% of the cases. Bacteria
were gram negative in 57.1% and gram positive in 42.9% of
positive cases. There was no difference in the proportion of the
different types of bacterial infection according to the anti-
microbial serology status (data not shown).
Clinical and laboratory predictors for the development of
bacterial infection. Of the clinical factors, the disease severity
by Child-Pugh stage (p= 0.035), the presence of ascites (OR: 2.83;
Table 2. Anti-microbial serological markers in patients with chronic liver diseases and healthy controls.
ASCA Anti-OMP PlusTM
Number IgA and/or IgG IgA
Liver cirrhosis with various etiology 286 110 (38.5%)* 179 (62.6%)*
Chronic HCV without cirrhosis 124 11 (8.9%)# 3 (2.4%)#
Autoimmune liver diseases without cirrhosis 266 59 (22.2%) 44 (16.5%)
PBC 153 31 (20.3%) 26 (17.0%)
PSC 59 18 (30.5%)&,w 9 (15.3%)H
AIH 54 10 (18.5%) 9 (16.7%)
Healthy controls 100 16 (16%) 20 (20%)
AIH= autoimmune hepatitis, HCV= viral hepatitis C, PBC= primary biliary cirrhosis, PSC = primary sclerosing cholangitis.
*p,0.001 between liver cirrhosis and chronic HCV, autoimmune liver diseases, healthy controls.
#p,0.001 between chronic HCV patients and autoimmune liver diseases, healthy controls.
&p= 0.04 between PSC and healthy controls.
wp,0.001 between PSC and chronic HCV.
Hp,0.01 between PSC and chronic HCV.
by using Fisher’s exact test or x2-test with Yates correction if appropriate.
doi:10.1371/journal.pone.0012957.t002
Table 3. Anti-microbial serological markers in patients with
liver cirrhosis according to the disease severity depicted by
Child-Pugh stages.
Child-Pugh stages
A (n =96) B (n=107) C (n=76)
ASCA IgA and/or IgG 23 (24.0%) 42 (39.3%) 45 (59.2%)*
ASCA IgA 15 (15.6%) 37 (34.6%) 43 (56.6%)*
ASCA IgG 14 (14.6%) 16 (15.0%) 18 (23.7%)
Anti-OMP PlusTM IgA 38 (39.6%) 77 (72.0%) 64 (84.2%)*
Multiple seropositivity 18 (17.7%) 38 (35.5%) 44 (57.9%)*
*P,0.001 for both by linear-by-linear association.
Child-Pugh stage were not available for 7 patients.
doi:10.1371/journal.pone.0012957.t003
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95% CI: 1.64–4.86, p,0.001) and co-morbidities (OR: 2.42; 95%
CI: 1.47–4.24, p= 0.001) were found to be risk factors for the
development of severe infections, using univariate analysis (x2-test
or x2-test with Yates correction).
Considering the anti-microbial antibodies individually, both the
presence (OR: 1.73, 95% CI: 1.02–2.92, p = 0.041) and the type of
ASCA positivity (not positive: 24.4%, IgA- or IgG- positive:
30.8%, IgA- and IgG-positive: 43.8%, p = 0.015 by linear-by-
linear association) were associated with the development of severe
infections. The same tendency was also observed for anti-OMP
PlusTM IgA positivity (21.5% vs. 31.5%, p= 0.069), but not for
LBP. Similarly, the severe infection rate increased in parallel to the
extent of both ASCA IgG and IgA serological responses (IgA IQR
titers: 1st quartile: 16.9%, 2nd quartile: 28.8%, 3rd quartile: 30.3%
and 4th quartile: 36.8%; ASCA IgG: 1st quartile: 18.6%, 2nd
quartile: 24.7%, 3rd quartile: 34.7% and 4th quartile: 35.2%;
p = 0.003 by linear by linear association for both).
The presence of serological response to multiple markers was
also significantly associated with the probability of developing
severe infections. The rate of the severe infection was 21.1%,
27.7%, 31.4% and 43.3% based on seropositivity, positive for 0, 1,
2 and 3 markers, respectively (p = 0.036 by linear-by-linear
association).
In a logistic regression analysis, the presence of ascites, co-
morbidities and ASCA positivity, but not LBP were independent
predictors of development of severe infections (Table 5).
3. Clinical and laboratory parameters associated with
time to first severe infection
In a Kaplan-Meier analysis, Child-Pugh stages, presence of
ascites, and co-morbidities were associated with time to first severe
infection by Breslow and LogRank (Figure 2). Of the serologic
markers, presence of ASCA (pBreslow = 0.03) and seropositivity to
multiple markers (pBreslow: 0.037) were associated with time to
first severe infection (Figure 2).
Figure 1. Anti-microbial antibody levels in patients with cirrhosis with various levels of severity, as depicted either by Child-Pugh
stages (A) or MELD score (B). A. Individual values are shown by black spots. Mean values with standard error bars are indicated in blue. Cut-off
values for positivity are 25 Units for all antibodies. P,0.001 between all groups by ANOVA post hoc Scheffe for ASCA IgA and anti-OMP PlusTM IgA
P =NS for ASCA IgG. B. MELD Q1-Q4 represent the groups of patients broken down by quartile: quartile1 patients have the lowest severity up to
quartile4, representing patients with the highest level of severity. P,0.001 between all groups by ANOVA post hoc Scheffe for ASCA IgA and anti-
OMP PlusTM IgA P =NS for ASCA IgG.
doi:10.1371/journal.pone.0012957.g001
Table 4. Anti-microbial serological markers in cirrhotic
patients according to the absence or presence of ascites.
Patients without
ascites
Patients with
ascites
(n =150) (n=136)
ASCA IgA and/or IgG 46 (30.7%) 63 (46.3%)*
ASCA IgA 39 (26.0%) 58 (42.6%)*
ASCA IgG 25 (16.7%) 24 (17.6%)
Anti-OMP PlusTM IgA 75 (50.0%) 103 (75.7%)#
Multiple seropositivity 39 (26.0%) 60 (44.1%)*
*p,0.01,
#p,0.001 between cirrhotic patients with or without ascites by x2-test with
Yates correction and linear-by-linear association for serological responses.
doi:10.1371/journal.pone.0012957.t004
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In a Cox-regression analysis, the Child-Pugh stage (p,0.001)
and co-morbidities (p = 0.006, OR: 1.83), but not seroreactivity
were associated with shorter time until the first infection (Table 6).
4. Clinical and laboratory parameters associated with
mortality
In total, 88 patients (30.8%) died. Of the clinical factors, the
disease severity by Child-Pugh stage (p,0.001), the presence of
ascites (OR: 3.17; 95% CI: 1.87–5.38, p,0.001) and co-
morbidities (OR: 1.71; 95% CI: 1.03–2.83, p= 0.038) were found
to be risk factors for mortality, using univariate analysis (x2-test or
x2-test with Yates correction) similar to the presence of both
ASCA IgA and IgG (OR: 1.75; 95% CI: 1.05–2.91, p= 0.032),
anti-OMP PlusTM (OR: 2.08; 95% CI: 1.20–3.62, p= 0.009) and
multiple serology positivity (p = 0.037). In addition, the presence of
ASCA IgA and/or IgG (pLogRank = 0.045, pBreslow = 0.05),
anti-OMP Plus (pLogRank = 0.009, pBreslow = 0.02) or multiple
seropositivity (pLogRank = 0.01, pBreslow = 0.02) were also asso-
ciated with time to death in a Kaplan-Meier analysis.
In contrast by logistic regression analysis, only Child-Phugh
stage (p,0.001) and presence of co-morbidities (p = 0.028–0.30),
and by Cox-regression analysis only Child-Pugh stage (p,0.001)
was associated with short term mortality and time to death.
Discussion
To our knowledge, this is the first report to investigate the
complex associations between anti-microbial serological responses
and the disease etiology along with severity in a large cohort of
patients suffering from various chronic liver diseases. In the
present study, we demonstrated that the presence of anti-microbial
antibodies in chronic liver diseases was mainly associated with the
presence of cirrhosis and was unrelated to the etiology. In the
absence of liver cirrhosis, the presence of antibodies was similar to
that observed in the controls. The rate of ASCA positivity in
patients with ALD and chronic HCV was equal to the findings of
previous studies [31,32,33]. As a result of the lower antibody rate
in their healthy control group, however, a significantly higher
ASCA prevalence was found in the ALD compared to healthy
controls.
The exact mechanism behind anti-microbial antibody forma-
tion is not fully understood. In the present study we aimed to
provide new pieces of this puzzle. The presence of anti-microbial
antibodies is not specific for certain diseases but the mechanism
behind their formation might be specific, however, linking
primarily different diseases. We hypothesized that the develop-
ment of anti-microbial antibodies is triggered by sustained
bacterial translocation from the gut to the systemic circulation as
a consequence of the enhanced intestinal permeability and
compromised mucosal immunity.
The OMP PlusTM IgA assay detects antibodies to a complex
mixture of bacterial proteins derived from one species of gram
positive and one species of gram negative gut bacteria having a
potential to translocation from the gut to the systemic circulation.
ASCAs are directed primarily against mannan cell-wall compo-
nents of different microorganisms [34] and occurred frequently in
some diseases associated with chronic bacterial translocation (e.g.
Crohn’s disease, celiac disease) [16,17,18,19,20]. Bacterial trans-
location is frequently reported in patients with liver cirrhosis,
especially in those with more severe liver dysfunction [35], as well
as in experimental cirrhosis in the presence of ascites [36]. The
present study demonstrated that both the seropositivity rates and
antibody titers showed a gradual increase according to the severity
of liver cirrhosis- Anti-microbial antibody titers reached the
highest value in patients with advanced liver cirrhosis. Further-
more, both the qualitative and quantitative serological responses
were also associated with the presence of ascites. The mechanisms
involved in bacterial translocation are related to the progression of
the liver disease [37,38]. Aerobic facultative gram negative bacilli,
which are only present in low numbers in the small bowel of
normal subjects, are found to be increased in jejunal flora of many
patients with cirrhosis. Small intestinal bacterial overgrowth exists
in approximately 60% of patients with cirrhosis [39], particularly
in those with ascites and advanced liver dysfunction [40]. Impaired
small intestinal motility [41] and decreased immunological defense
are thought to play a major role in its development [9]. Disruption
of the gut-barrier integrity secondary to mucosal blood flow
changes, oxidative damage, upregulation of proinflammatory
cytokines and nitric oxide also enhance bacterial translocation
[42]. In the present study, the dominant elevation of IgA type
antibodies over IgG one may suggest that compromised mucosal
immunity play a principal role in the development of anti-
microbial antibody formation in patients with advanced liver
cirrhosis.
Gram negative bacteria are the most frequently translocating
bacteria in patients with liver cirrhosis [9]. Anti-gal antibodies
directed to the surface antigen of gram negative bacteria have
been found to be significantly associated with individuals with
stage III or greater fibrosis, regardless of the etiology of liver
diseases. Patients with increased levels of anti-gal antibody had
increased levels of endotoxin and other markers of bacterial
exposure [43]. In our study, anti-OMP PlusTM IgA antibodies,
which include antibodies to targeting bacterial proteins derived
from both gram negative and gram positive gut bacteria, were
detected in 62.6% of antibodies in cirrhotic patients, about 60%
more frequent than ASCA IgG and/or IgA antibodies.
Furthermore, PSC was the only subgroup in which we detected
significantly higher prevalence of ASCA, even in the lack of
advanced liver cirrhosis. ASCA positivity was comparable to that
in the study of Muratori et al. (30.5% vs. 44%) [31] and did not
differ according to the concomitant inflammatory bowel disease.
This finding also supports our hypothesis that anti-microbial
antibody formation is particularly driven by sustained bacterial
translocation. Because of the development of biliary stenotic
lesions in PSC, the likelihood of infection is relatively high. These
lesions have been correlated with increased susceptibility to
infections by enteric gram negative pathogens [44]. Increased
prevalence of anti-microbial antibodies in other clinical conditions
complicated by bacterial translocation would also support our
Table 5. Logistic regression: Predictive factors for severe
bacterial infection in patients with liver cirrhosis.
Factor Coefficient P value OR 95% CI
Female gender 0.355 0.228 1.43 0.80–2.54
Child-Pugh stage 20.096 0.669 0.91 0.58–1.41
Ascites 0.481 0.004 1.62 1.16–2.25
LBP level (.26,
236 ng/ml)
20.094 0.85 0.92 0.44–1.89
Co-morbidities 0.796 0.005 2.22 1.27–3.86
ASCA IgA and/or IgG 0.491 0.018 1.63 1.09–2.45
The coefficient is equivalent to the natural log of the OR; p value: level of
significance;
OR: odds ratio; 95% CI: 95% confidence interval.
doi:10.1371/journal.pone.0012957.t005
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hypothesis. However, no data are available in the current
literature regarding this.
Genetically-based loss of tolerance toward the gut flora was
suggested to trigger the formation of anti-microbial antibodies in
Crohn’s disease [45]. Enhanced bacterial translocation associat-
ed to nucleotide-binding oligomerization containing domain 2/
caspase recruitment domain 15 (NOD2/CARD15) variants only
explains partially high prevalence of these antibodies. The
occurrence of ASCA was higher by 25% in Crohn’s disease
patients carrying at least one NOD2/CARD15 mutation as
compared to the non-carrier ones [46,47,48]; however, the
ASCA prevalence was also high in this latter group. Further-
more, the fact that there is a considerably higher prevalence of
anti-microbial antibodies both in liver cirrhosis and untreated
celiac disease without higher carriage of variant NOD2/
CARD15 alleles [16,49,50], suggests that genetically-based loss
of tolerance toward the gut flora [45] is not the only mechanism
triggering the anti-microbial antibody formation. The acquired
structural and functional impairment of the small bowel as well as
the variation in the microbial flora may be an important, if not
primary, factor inducing bacterial translocation with an en-
hanced anti-microbial antibody formation in all of these
gastrointestinal disorders.
Elevated LBP level was suggested to be related to bacterial
passage from the gut to the circulation without overt infection in
cirrhotic patients with ascites on the basis of the fact that patients
with increased serum LBP level were four times more likely to
have severe bacterial infection during follow-up than patients with
normal LBP [51]. For this reason, we examined whether any
association existed between serum LBP level and the presence of
anti-microbial antibodies. Serum LBP levels were not different in
patients with and without ASCA IgG/IgA, and anti-OMP PlusTM
IgA antibodies or in the case a combination of these antibodies
were used. At the same time, LBP was found to be an acute phase
marker during bacterial infection. The best accuracy for LBP was
detected at 26 236 ng/L based on the ROC analysis with a
sensitivity of 60.2% and a specificity of 75.1%.
One of the limitations of our study is that the expression of the
anti-microbial antibodies was not assessed directly in the intestinal
mucosa or in the organs to which gut bacteria are translocated
(e.g. liver or ascites). Instead, to support our hypothesis that anti-
microbial antibody formation might be a consequence of chronic
bacterial translocation, we conducted a follow-up observational
study to examine whether the presence of these antibodies may
have been associated to the development of severe bacterial
infections. The presence and the extent of anti-microbial
serological response was found to be associated to severe bacterial
infections overall and the time to first infection was also shorter in
patients with multiple seropositivity. Recently common variants of
nucleotide-binding oligomerization containing domain 2/caspase
recruitment domain 15 (NOD2/CARD15) linked to impaired
mucosal barrier function were also reported to be risk factors for
spontaneous bacterial peritonitis in liver cirrhosis [52]. On the
contrary to genetic variation of this and other pathogen-associated
molecular patterns’ receptors [53], the presence of anti-microbial
antibodies were not associated with either the infection-related or
the overall mortality in multivariate analysis suggesting that they
have no role in the progression (injury, fibrogenesis) and the
bacterial complication of the liver cirrhosis. Similarly, no data
suggest any pathogenetic role in other diseases associated with
high frequency of anti-microbial antibodies for the present.
However, anti-microbial antibodies might be feasible medium-
term biomarkers for future clinical applications regarding severity
of liver cirrhosis and prediction of bacterial complications.
Concuring with the findings of Rieder et al. [54] in patients with
inflammatory bowel disease, we found the ASCA and anti-
OMPTMantibody stability to be acceptable on the medium-term.
Duplicate samples, taken from the same patients at different time
points and assayed for these antibodies, showed no significant
variation in serum levels. Only 9.7% (6/62) of the patients
changed their antibody status during the median period of 204
days [IQR, 71–245 days].
In summary, the presence of anti-microbial antibodies was
common in patients with liver cirrhosis and was associated
with advanced disease, the existence of portal hypertension, but
not with the disease etiology. Serological response to various
microbial components might be considered as a universal
marker for the enhanced translocation of gut microflora or a
reflection of compromised mucosa immunity. To determine
whether assessment of the anti-microbial serological markers has
any additional benefit over the currently used factors (disease
severity stage, presence of ascites) for the prediction of infections
in patients with cirrhosis further long-term prospective studies
are warranted.
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Table 6. Summary of Cox model: factors affecting time to
first severe bacterial infection.
p Hazard Ratio 95% CI
Co-morbidities 0.006 1.83 1.19–2.80
Child-Pugh stage ,0.001
Child A reference
Child B 0.048 1.71 1.01–2.91
Child C ,0.001 3.26 1.90–5.59
Seropositivity to
ASCA/anti-OMP PlusTM
0.77 1.04 0.78–1.39
p value: level of significance; 95% CI: 95% confidence interval.
doi:10.1371/journal.pone.0012957.t006
Figure 2. Association between Child-Pugh stages (A), presence of ascites (B), co-morbidities (C), seropositivity to ASCA/anti-OMP
PlusTM (D) and the development of severe bacterial infection in patients with liver cirrhosis. Infection-free survival refers to the
proportion of patients in the cohort without infection at a given time during the follow-up. A. Patients with Child C stage cirrhosis were at higher risk
for developing severe bacterial infections compared to patients with Child A or B disease. B. Patients with ascites were at higher risk for developing
severe bacterial infections compared to patients without ascites. C. Patients with co-morbidity were at higher risk for developing severe bacterial
infections compared to patients without co-morbidity. D. Patients with multiple seropositivity were at higher risk for developing severe bacterial
infections compared to seronegative ones.
doi:10.1371/journal.pone.0012957.g002
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